Live tape
Top 8, mentions 7d8,897GOOGL1,697 mentions▲ +0.04MRNA1,370 mentions▲ +0.09SNDK1,289 mentions▲ +0.11META1,129 mentions▲ +0.03NVDA1,050 mentions▲ +0.08SPCX902 mentions▲ +0.08NBIS744 mentions▲ +0.09MSFT716 mentions▲ +0.05

Equity · Healthcare

ARWR

Arrowhead Pharmaceuticals, Inc. · NasdaqGS

$89 +1.14% 1D Finazon · prior-day close · Aug 19, 2026
Price · Chart
Our own end-of-day closes 61 sessions
$90 $70 22 May 19 Aug

The line runs $75 on 22 May through $89 on 19 August, on a scale from $70 to $90. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of ARWR over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 61 sessions over that window: $75 on 22 May 2026 through $89 on 19 August 2026.

Market cap $12.4B
52-week range $17 – $89.61
Avg volume 382.9K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 19, 2026

ARWR insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 15 Jun 2026
Open-market buys 0
Open-market sells 0
Non-trade filings 1

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
15 Jun 2026 Cohen Matthew Gregory Director Award 11,882

ARWR reported financials

SEC EDGAR XBRL

ARWR reported revenue of $829.4M for the fiscal year ended 30 Sep 2025. Net income over the same period was −$1.6M.

Figure Reported Period
Revenue $829.4M 30 Sep 2025 fiscal year
Net income −$1.6M 30 Sep 2025 fiscal year
Diluted EPS −$0.01 30 Sep 2025 fiscal year
Total assets $2.1B 30 Jun 2026 at period end
Total equity $465.5M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

ARWR earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q3 2026 $-1.36 —
31 Mar 2026 Q2 2026 $-0.93 —
31 Dec 2025 Q1 2026 $0.22 —
30 Sep 2025 FY 2025 $-0.01 —
30 Jun 2025 Q3 2025 $-1.26 —
31 Mar 2025 Q2 2025 $2.75 —
31 Dec 2024 Q1 2025 $-1.39 —
30 Sep 2024 FY 2024 $-5.00 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

ARWR institutional holders

SEC Form 13F

9 of the 45 institutional funds we track reported a ARWR position for the quarter ended 30 Jun 2026 — a combined $467.1M; the latest of those filings landed 14 Aug 2026.

Fund Action Shares Value
Baker Bros. Advisors Held (±25%) 1,992,783 $162.4M
Fisher Asset Management Held (±25%) −14.0% shares 957,691 $78.1M
Two Sigma Investments Added +1,521.8% shares 580,609 $47.3M
Balyasny Asset Management Added +128.1% shares 470,754 $38.4M
Renaissance Technologies Trimmed −54.8% shares 468,921 $38.2M
D. E. Shaw & Co. Trimmed −63.5% shares 431,560 $35.2M
Millennium Management New position 329,337 $26.8M
Marshall Wace Added +69.9% shares 305,031 $24.9M
AQR Capital Management Held (±25%) +18.9% shares 198,842 $15.8M
Bridgewater Associates Exited

Source: SEC EDGAR 13F filings

ARWR fails-to-deliver

SEC CNS data

On 31 Jul 2026, 671 shares of ARWR failed to deliver (about $59K).

Settlement date Shares failed Notional % of shares out
31 Jul 2026 671 $59K <0.001%
20 Jul 2026 146 $11K <0.001%
17 Jul 2026 57 $4K <0.001%
08 Jul 2026 28,090 $2.4M 0.020%

Source: SEC fails-to-deliver (CNS) data